Information Provided By: 
Fly News Breaks for March 25, 2019
DERM
Mar 25, 2019 | 07:58 EDT
Needham analyst Serge Belanger raised his price target on Dermira to $22 and kept his Buy rating, saying the company's lebrikizumab phase 2B trial results demonstrated that it delivered on all 3 product attributes of efficacy, safety and dosing in treating atopic dermatitis. The analyst notes that the new price target reflects "significant de-risking and increased potential of the lebri program" as he expects Dermira to begin phase 3 trials later this year with results anticipated in 2021.
News For DERM From the Last 2 Days
There are no results for your query DERM
